•  

    The patients profiles shown below may remind you of similar patients you have in your consultancy. Read the patient profiles and discover how Praluent® helps to reduce the risk of CV events for ACS patients with uncontrolled LDL-C1.

    Susan

    Susan has type 2 diabetes and had her second cardiac event 4 months ago.
    ~1 in 6 patients like Susan had a MACE over a median of 2.8 years2.

    Diagnosis

    Susan was diagnosed with type 2 diabetes 12 years ago. She had her first MI aged 59 years following her husband’s death and a second event 4 months ago.

    Current treatment

    • Cardio-protective medication as recommended by NICE5, including 40 mg atorvastatin (maximum tolerated dose)6*
      • Diabetes is well controlled and all other secondary prevention measures are optimised
      • Cholesterol = 6.5 mmol/L
      • Non-HDL-C = 5.1 mmol/L

    Additional treatment with PCSK9i

    • Her LDL-C is above recommended ESC7 targets despite lipid-lowering treatment
    • Susan meets the NICE criteria for prescribing PRALUENT8

    Susan meets the NICE criteria for prescribing PRALUENT®8

    • Patients with a LDL-C level like Susan are classified as a very high risk of CVD8.

    Read the NICE recommended patient groups for alirocumab in the NICE Guidance section.

    • Odyssey Outcomes included 5444 patients similar to Susan with diabetes1.

    Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.

    * Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
    The prescriber should follow relevant professional guidance taking full responsibility for the decision.

    Not real patients, for illustrative purposes only

    Dominic

    Dominic is 58 years old and has just had his second MI.
    ~1 in 11 patients like Dominic had a another event within one year3.

    Diagnosis

    At 54 years old, Dominic experienced an episode of unstable angina.

    At 58 years old, Dominic has experienced a second ACS event.

    Current treatment

    • Cardio-protective medication as recommended by NICE,5 including 80 mg atorvastatin6*
      • All other secondary prevention measures are optimised
      • Cholesterol = 6.1 mmol/L
      • Non-HDL-C = 5.2 mmol/L
      • LDL-C = 3.6 mmol/L

    Additional treatment with PCSK9i

    • His LDL-C is above recommended ESC targets7 despite lipid-lowering treatment
    • Dominic meets the NICE criteria for prescribing PRALUENT8

    Dominic meets the NICE criteria for prescribing PRALUENT®8

    • Patients with a LDL-C level like Dominic are classified as a very high risk of CVD8.

    Read the NICE recommended patient groups for alirocumab in the NICE Guidance section.

    • Odyssey Outcomes included 3633 patients similar to Dominic with a prior MI before the index ACS event1.

    Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.

    * Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
    The prescriber should follow relevant professional guidance taking full responsibility for the decision.

    Not real patients, for illustrative purposes only

    Mary

    Mary has hypercholesterolaemia and had a recent ACS event.
    ~1 in 2 FH patients like Mary will had at least 1 CV event in the next 10 years4.

    Diagnosis

    Mary has FH, confirmed by genetic testing 4 years ago, and recently had an episode of UA.

    She is careful with her diet and exercises intensely.

    Current treatment

    • 80 mg atorvastatin* + ezetimibe 10 mg
      • Cholesterol = 7.7 mmol/L
      • Non-HDL-C = 5.9 mmol/L
      • LDL-C = 4.9 mmol/L

    Additional treatment with PCSK9i

    • Her LDL-C is above recommended ESC targets7 despite lipid-lowering treatment
    • Mary meets the NICE criteria for prescribing PRALUENT8

    Mary meets the NICE criteria for prescribing PRALUENT®8

    • FH patients with CVD like Mary are classified in the treatment group for alirocumab8.

    Read the NICE recommended patient groups for alirocumab in the NICE Guidance section.

    • Odyssey Outcomes included 6773 patients similar to Mary with a family history of premature coronary heart disease1.

    Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.

    * Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
    The prescriber should follow relevant professional guidance taking full responsibility for the decision.

    Not real patients, for illustrative purposes only

    Ajay

    Ajay is 65 and has suffered his first heart attack.
    ~1 in 16 patients like Ajay may have an event within the first year post ACS3.

    Diagnosis

    Ajay was admitted to hospital 6 months ago with a STEMI aged 65 years. He was treated by coronary angiography, with follow-on primary PCI and discharged.

    Current treatment

    • Cardio-protective medication as recommended by NICE,5 including 80 mg atorvastatin6*
    • All other secondary prevention measures are optimised
    • Lipid values:
      • Cholesterol = 7.4 mmol/L
      • Non-HDL-C = 5.6 mmol/L
      • LDL-C = 4.6 mmol/L

    Additional treatment with PCSK9i

    • Ajay’s LDL-C is above recommended ESC targets despite lipid-lowering treatment7
    • Ajay meets the NICE criteria for prescribing PRALUENT8

    Ajay meets the NICE criteria for prescribing PRALUENT®8

    • Patients with a LDL-C level like Ajay are classified as a high risk of CVD8.

    Read the NICE recommended patient groups for alirocumab in the NICE Guidance section.

    • All patients in Odyssey Outcomes were similar to Ajay with an index ACS events <12 months ago1.

    Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.

    * Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
    The prescriber should follow relevant professional guidance taking full responsibility for the decision.

    Not real patients, for illustrative purposes only

    Not real patients, for illustrative purposes only

    Do you want more information?
    Request a representative to contact you here or sign-up to receive updates here.

    Praluent® Indication

    Primary hypercholesterolaemia and mixed dyslipidaemia9

    Praluent® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet :

    • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
    • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

    Established atherosclerotic cardiovascular disease9

    Praluent® is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors :

    • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies, or
    • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

    ODYSSEY OUTCOMES

    PRALUENT® EFFICACY IN THE ODYSSEY OUTCOMES TRIAL

    Learn more

    ODYSSEY OUTCOMES

    TRIAL DESIGN

    Learn more

    NICE GUIDANCE

    Learn more
    1. Schwartz G, et al. N Engl J Med 2018;379(22):2097–2107.
    2. Kausik K, et al. Lancet Diabetes Endocrinol 2019; 7:618-628
    3. Canivell S, PLoS One 2018; 13e0195174.
    4. Villa G, Eur Heart J. 2017; 3:274-280
    5. NICE Pathways. Acute coronary syndromes: secondary prevention and rehabilitation overview. Available at https://pathways.nice.org.uk/pathways/acute-coronary-syndromes- secondary-prevention-and-rehabilitation. Accessed August 2021.
    6. National Institute of Health and Care Excellence (NICE). CG181 Published June 2016. Last updated September 2016.
    7. Mach F et al. Eur Heart J. 2019; 00:1-78. 8.
    8. National Institute of Health and Care Excellence (NICE). TA393. Published June 2016.
    9. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed August 2021.